@article{doka_suter_mastromauro_bennett_hess_2022, title={Doxorubicin for treatment of histiocytic sarcoma in dogs: 31 cases (2003-2017)}, volume={260}, ISSN={["1943-569X"]}, DOI={10.2460/javma.21.11.0498}, abstractNote={To evaluate the efficacy of doxorubicin for treatment of histiocytic sarcoma (HS) in dogs, whether administered as the sole treatment or as an adjunct to surgery or radiation therapy.31 client-owned dogs with localized or disseminated HS examined between 2003 and 2017.Medical records were reviewed retrospectively, and data were collected. The Kaplan-Meier method was used to estimate time-to-progression from the date of first doxorubicin administration and survival time from initial diagnosis. Factors that could be associated with poorer outcomes with doxorubicin treatment were analyzed with log-rank tests.The objective response rate (ORR) was 26%. When stratified by disease status, dogs with localized and disseminated forms experienced 43% and 21% ORRs, respectively. Median time to progression after initiating doxorubicin treatment (n = 30 dogs) was 42 days. Median survival time from initial diagnosis to death (n = 29 dogs) was 169 days. Complete responses were obtained in only 2 dogs that had localized disease and received multimodality therapy.Benefits of doxorubicin administration in canine HS are modest, with a limited ORR and delay in tumor progression, and are comparable to effects attained with other single-agent regimens.}, number={14}, journal={JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION}, author={Doka, Rhiannon M. and Suter, Steven E. and Mastromauro, Michael L. and Bennett, Ashley L. and Hess, Paul R.}, year={2022}, month={Nov}, pages={1827–1833} }